Λογότυπο www.galinos.gr Beta
 

Ιατροφαρμακευτική πληροφόρηση για τον επαγγελματία υγείας

Φάρμακα Δραστικές ουσίες Συμπληρώματα διατροφής Έλεγχος συγχορήγησης Νόσοι ICD-10
Κλαύδιος Γαληνός
Είσοδος χρηστών
Όνομα χρήστη
Συνθηματικό
Εικονίδιο Είσοδος χρήστη
Εικονίδιο Δωρεάν εγγραφή
Εικονίδιο Ανανέωση συνθηματικού

Ακολουθήστε μας Λογότυπο Facebook Λογότυπο Twitter

Αναζήτηση σε 63811 καταχωρήσεις
Εικονίδιο αναζήτησης

Βιβλιογραφική αναφορά

Προτάσεις

SPC, UK: Tractocile 7.5 mg/ml Solution for Injection (2005)

Εκδότης

Εκδότης Ferring Pharmaceuticals Ltd
Διεύθυνση Drayton Hall, Church Road, West Drayton, UB7 7PS, UK
Σφάλμα Για την προβολή της πλήρους καταχώρησης χρειάζεται να έχετε συνδρομή σε ισχύ (αγορά συνδρομής).
Ολοκληρώνοντας τη διαδικασία δωρεάν εγγραφής θα αποκτήσετε, χωρίς καμία δέσμευση εκ μέρους σας, συνδρομή διάρκειας 30 ημερών.

Περιεχόμενα

Name of the medicinal product

TRACTOCILE 7.5 mg/ml solution for injection.

Qualitative and quantitative composition

One ml solution contains 7.5 mg atosiban free-base in the form of atosiban acetate. For excipients, see ...

Pharmaceutical form

Solution for injection. Visual appearance: clear, colourless solution without particles.

Therapeutic indications

TRACTOCILE is indicated to delay imminent pre-term birth in pregnant women with: regular uterine contractions ...

Posology and method of administration

Treatment with TRACTOCILE should be initiated and maintained by a physician experienced in the treatment ...

Contraindications

TRACTOCILE should not be used in the following conditions: Gestational age below 24 or over 33 completed ...

Special warnings and precautions for use

When atosiban is used in patients in whom premature rupture of membranes cannot be excluded, the benefits ...

Interaction with other medicinal products and other forms of interaction

It is unlikely that atosiban is involved in cytochrome P450 mediated drug-drug interactions as in vitro ...

Pregnancy and lactation

Atosiban should only be used when pre-term labour has been diagnosed between 24 and 33 completed weeks ...

Effects on ability to drive and use machines

Not applicable.

Undesirable effects

Possible undesirable effects of atosiban were described for the mother during the use of atosiban in ...

Overdose

Few cases of atosiban overdosing were reported, they occurred without any specific signs or symptoms. ...

Pharmacodynamic properties

Pharmacotherapeutic group: Other gynecologicals ATC code: G02CX01 TRACTOCILE contains atosiban (INN), ...

Pharmacokinetic properties

In healthy non-pregnant subjects receiving atosiban infusions (10 to 300 micrograms/min over 12 hours), ...

Preclinical safety data

No systemic toxic effects were observed during the two-week intravenous toxicity studies (in rats and ...

List of excipients

Mannitol Hydrochloric acid 1M Water for injections

Incompatibilities

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal ...

Shelf life

2 years. Once the vial has been opened, the product must be used immediately.

Special precautions for storage

Store in a refrigerator (2°C 8°C). Store in the original package.

Nature and contents of container

One vial of solution for injection contains 0.9 ml solution, corresponding to 6.75 mg atosiban. Colourless ...

Special precautions for disposal and other handling

The vials should be inspected visually for particulate matter and discoloration prior to administration. ...

Marketing authorization holder

Ferring AB Soldattorpsvägen 5 Box 30 047 SE 20061 Limhamn Sweden

Marketing authorization number(s)

EU/1/99/124/001

Date of first authorization / renewal of the authorization

20 January 2005.

Date of revision of the text

January 2005.
Απαγορεύεται η αναπαραγωγή και αναδιανομή. Το έργο επεξεργασίας των παραπάνω πληροφοριών αποτελεί πνευματική ιδιοκτησία της Ergobyte Πληροφορική Α.Ε. και προστατεύεται από τη νομοθεσία περί πνευματικών δικαιωμάτων.